DEXCOM INC Files Definitive Proxy Statement

Ticker: DXCM · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 1093557

Dexcom INC DEF 14A Filing Summary
FieldDetail
CompanyDexcom INC (DXCM)
Form TypeDEF 14A
Filed DateApr 22, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$3.62 billion, $2.29 billion, $597.7 million, $541.5 million, $748.5 million
Sentimentneutral

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, DEXCOM INC, Corporate Governance, Shareholder Meeting

TL;DR

<b>DEXCOM INC has filed its Definitive Proxy Statement for the period ending May 22, 2024.</b>

AI Summary

DEXCOM INC (DXCM) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. DEXCOM INC filed a Definitive Proxy Statement (DEF 14A) on April 22, 2024. The filing covers the period ending May 22, 2024. The company's fiscal year ends on December 31. DEXCOM INC is incorporated in Delaware. The company's business and mailing address is 6340 Sequence Drive, San Diego, CA 92121.

Why It Matters

For investors and stakeholders tracking DEXCOM INC, this filing contains several important signals. This filing is a standard procedural document required for public companies to solicit shareholder votes. It provides detailed information on executive compensation, board of directors, and other governance matters, which are crucial for investors to understand before voting.

Risk Assessment

Risk Level: low — DEXCOM INC shows low risk based on this filing. The filing is a routine DEF 14A, indicating no immediate or significant new risks are being disclosed beyond standard corporate governance information.

Analyst Insight

Review the executive compensation and board proposals within the proxy statement to understand potential impacts on corporate governance and shareholder value.

Key Numbers

Key Players & Entities

FAQ

When did DEXCOM INC file this DEF 14A?

DEXCOM INC filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by DEXCOM INC (DXCM).

Where can I read the original DEF 14A filing from DEXCOM INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by DEXCOM INC.

What are the key takeaways from DEXCOM INC's DEF 14A?

DEXCOM INC filed this DEF 14A on April 22, 2024. Key takeaways: DEXCOM INC filed a Definitive Proxy Statement (DEF 14A) on April 22, 2024.. The filing covers the period ending May 22, 2024.. The company's fiscal year ends on December 31..

Is DEXCOM INC a risky investment based on this filing?

Based on this DEF 14A, DEXCOM INC presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating no immediate or significant new risks are being disclosed beyond standard corporate governance information.

What should investors do after reading DEXCOM INC's DEF 14A?

Review the executive compensation and board proposals within the proxy statement to understand potential impacts on corporate governance and shareholder value. The overall sentiment from this filing is neutral.

How does DEXCOM INC compare to its industry peers?

DEXCOM INC operates in the surgical and medical instruments and apparatus industry (SIC 3841).

Are there regulatory concerns for DEXCOM INC?

The filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

Industry Context

DEXCOM INC operates in the surgical and medical instruments and apparatus industry (SIC 3841).

Regulatory Implications

The filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

  1. Analyze the proposals presented for shareholder vote in the proxy statement.
  2. Review the compensation details for named executive officers.
  3. Examine the composition and independence of the Board of Directors.

Key Dates

Year-Over-Year Comparison

This is the initial filing of the Definitive Proxy Statement for the 2024 proxy season, filed on April 22, 2024.

Filing Stats: 4,510 words · 18 min read · ~15 pages · Grade level 12.5 · Accepted 2024-04-22 16:32:36

Key Financial Figures

Filing Documents

EXECUTIVE COMPENSATION 30

EXECUTIVE COMPENSATION 30 Compensation Discussion and Analysis 30 Fiscal 2023 Corporate Performance 31 Fiscal 2023 Compensation Overview 32 Compensation Philosophy and Objectives 34 2023 Executive Compensation Policies and Practices at a Glance 35 Stockholder Advisory Vote on Executive Compensation 35 Compensation Decision-Making Process 35 Compensation Peer Group 36 Competitive Positioning 37 Fiscal 2023 Compensation Elements 38 Post-Employment Compensation 50 Stock Ownership Guidelines and CEO Holding Requirement 50 Insider Trading Policy; Anti-Hedging 51 Compensation Risk Controls 51 Compensation Recovery Policy 51 Table of Contents Tax and Accounting Considerations 51 Compensation Committee Report 52 SUMMARY OF EXECUTIVE COMPENSATION 53 2023 Summary Compensation Table 53 Grants of Plan-Based Awards for 2023 55 Outstanding Equity Awards at December 31, 2023 57 2023 Option Exercises and Stock Vested 58 Executive Nonqualified Deferred Compensation Plan 58 Severance and Change in Control Arrangements 60 Pay versus Performance 63 Chief Executive Officer Pay Ratio 65 Equity Compensation Plan Information 66 Risks from Compensation Policies and Practices 66

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 67

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 67 DELINQUENT SECTION 16(a) REPORTS 69 CERTAIN TRANSACTIONS WITH RELATED PERSONS 69 STOCKHOLDER PROPOSALS FOR ANNUAL MEETING 70 HOUSEHOLDING OF PROXY MATERIALS 71 PROPOSAL NO. 4 - STOCKHOLDER PROPOSAL: PAY EQUITY DISCLOSURE 72 Stockholder Proposal and Supporting Statement 72 Dexcom's Statement in Opposition to Proposal No. 4 73 PROPOSAL NO. 5 - STOCKHOLDER PROPOSAL: TRANSPARENCY IN LOBBYING 76 Stockholder Proposal and Supporting Statement 76 Dexcom's Statement in Opposition to Proposal No. 5 77 OTHER MATTERS 78 INFORMATION ABOUT THE PROXY MATERIALS AND THE ANNUAL MEETING 79 ANNUAL REPORTS 84 ANNEX A - RECONCILIATION BETWEEN GAAP AND NON-GAAP FINANCIAL MEASURES 85 PROXY CARD 87 Table of Contents PROPOSAL NO. 1 Election of Directors Our Board recommends a vote "FOR" the following ten nominees for election to our Board, each to hold office until our 2025 annual meeting of stockholders: 1) Kevin R. Sayer 2) Steven R. Altman 3) Nicholas Augustinos 4) Richard A. Collins 5) Karen Dahut 6) Rimma Driscoll 7) Mark G. Foletta 8) Bridgette P. Heller 9) Kyle Malady 10) Eric J. Topol, M.D. THE BOARD RECOMMENDS A VOTE FOR THE ELECTION OF THE NOMINEES NAMED ABOVE. At each annual meeting of stockholders, the terms of each of our incumbent directors expire and all members of our Board are elected. Ten directors are to be elected at this Annual Meeting, each to serve until our 2025 annual meeting of stockholders or until such director's earlier death, resignation or removal. On the Nominating and Governance Committee's recommendation, the Board has nominated each of the above listed nominees for election at the Annual Meeting. Each of the nominees is a current director of the company. Each nominee has consented to being named in this Proxy Statement and has agreed to continue to serve as a director if elected, and we have no reason to believe that any nominee will be unable

: Gender Identity Female Male

Part I: Gender Identity Female Male Directors 4 7

: Demographic Background

Part II: Demographic Background African American or Black 1 — White 3 7 LGBTQ+ 1 Table B below presents diversity information for the director nominees. Table B Nominee and Continuing Director Demographics Total Number of Directors 10

: Gender Identity Female Male

Part I: Gender Identity Female Male Directors 3 7

: Demographic Background

Part II: Demographic Background African American or Black 1 — White 2 7 LGBTQ+ 1 4 Table of Contents Nominee Director Biographies Kevin R. Sayer Chairperson of the Board, President and CEO Age: Joined the Board: Committees: Other Current Public Company Boards or Officer Experience: 66 2007 None None Kevin R. Sayer has served on our Board since November 2007, as our President and Chief Executive Officer ("CEO") since January 2015 and as our Chairperson of the Board ("Chairperson") since July 2018. Mr. Sayer has been our President since 2011, and from January 2013 until January 2015, Mr. Sayer also served as our Chief Operating Officer. From April 2007 to December 2010, Mr. Sayer served as Chief Financial Officer of Biosensors International Group, Ltd. ("Biosensors"), a medical technology company developing, manufacturing and commercializing medical devices used in interventional cardiology and critical care procedures. Prior to joining Biosensors, from May 2005 to April 2007, Mr. Sayer served as an independent healthcare and medical technology industry consultant. From March 2004 to May 2005, Mr. Sayer was Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., a company offering clinical reference laboratory services. From August 2002 to March 2004, Mr. Sayer worked as an independent healthcare and medical technology industry consultant. Mr. Sayer served as Chief Financial Officer of MiniMed, Inc. from May 1994 until it was acquired by Medtronic, Inc. in August 2001. Mr. Sayer served as Vice President and General Manager of Medtronic MiniMed after the acquisition until August 2002. Mr. Sayer is a Certified Public Accountant (inactive) and received his Master's Degree in Accounting and Information Systems concurrently with a B.A., both from Brigham Young University. As CEO, Mr. Sayer has direct responsibility for our strategy and operations. Steven R. Altman Independent Director Age: Joined the Board: Committees:

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing